🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Waldenstrom Macroglobulinemia

SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing NCT06550427n/a1 site📍 Taipei National Taiwan University Hospital · Tests: ctDNA analyzed by phased variant Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma NCT04840602Phase 2146 sites📍 Tucson📍 Tucson📍 Irvine National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia NCT05640102n/a8 sites📍 Huntsville📍 Mobile📍 Duarte BeiGene · Tests: Zanubrutinib Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors NCT05643235NA1 site📍 New Hyde Park Northwell Health · Tests: Medtronic LINQ-2 Insertable Cardiac Monitor (ILR) Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) NCT00923507n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader NCT05294731Phase 1, Phase 229 sites📍 Bengbu📍 Hefei📍 Beijing BeOne Medicines · Tests: Tacabrutideg Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study NCT06151730n/a1 site📍 Rochester Mayo Clinic · Tests: Non-Interventional Study Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia NCT04893564NA1 site📍 Amiens Centre Hospitalier Universitaire, Amiens · Tests: bone marrow sample, blood sample This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process NCT07160270n/a1 site📍 København Ø Copenhagen University Hospital, Rigshospitalet A Study of APG-3288 in Relapsed/Refractory Blood Cancers NCT07424833Phase 16 sites📍 Los Angeles📍 Jacksonville📍 Grand Rapids Ascentage Pharma Group Inc. · Tests: APG-3288 Preliminary Assessment of [18F]BL40 in PET/CT Scans NCT06224309n/a1 site📍 Vancouver British Columbia Cancer Agency · Tests: 18F-BL40 PET/CT, 18F-FDG PET/CT, Routine Blood Draw - Phase 1 only A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022Phase 162 sites📍 Duarte📍 San Francisco📍 Denver Nurix Therapeutics, Inc. · Tests: NX-5948 AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737Phase 11 site📍 Palo Alto Stanford University · Tests: CD22CART Infusion Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011n/a1 site📍 Freiburg im Breisgau iOMEDICO AG · Tests: Routine care as per site standard. Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy NCT07426484Phase 42 sites📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Cosibelimab, Prednisone, Sirolimus, Everolimus A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies NCT05780034Phase 19 sites📍 Denver📍 Sarasota📍 Chapel Hill Accutar Biotechnology Inc · Tests: AC676 Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905Phase 1, Phase 22 sites📍 Richmond📍 Nedlands ModeX Therapeutics, An OPKO Health Company · Tests: MDX2003 Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma NCT05326308n/a2 sites📍 Salzburg📍 Lübeck iOMEDICO AG · Tests: Zanubrutinib, Obinutuzumab A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies NCT06708897Phase 15 sites📍 Louisville📍 Chapel Hill📍 Cincinnati Lomond Therapeutics Holdings, Inc. · Tests: Lonitoclax (ZE50-0134) A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies NCT07609862Phase 1, Phase 21 site📍 Tianjin Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Lacutoclax+Rocbrutinib A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia NCT06986174Phase 21 site📍 Boston Shayna Sarosiek, MD · Tests: Pacritinib Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880NA1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Exercise, Diet AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma NCT05602363Phase 113 sites📍 Orange📍 Miami Beach📍 Tampa Carna Biosciences, Inc. · Tests: Docirbrutinib A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) NCT07101328Phase 151 sites📍 Duarte📍 Aurora📍 Denver Eli Lilly and Company · Tests: LY4152199 - IV Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019Phase 136 sites📍 Gilbert📍 Newark📍 Pompano Beach Schrödinger, Inc. · Tests: SGR-1505 A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) NCT07231952Phase 29 sites📍 Boston📍 Boston📍 Basking Ridge Memorial Sloan Kettering Cancer Center · Tests: Pirtobrutinib, Venetoclax, Rituximab Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia NCT05099471Phase 214 sites📍 Bielefeld📍 Chemnitz📍 Kempten Christian Buske · Tests: Venetoclax; Rituximab, DRC
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy